Technical Analysis for MPSYF - Morphosys Ag

Grade Last Price % Change Price Change
grade A 120.7 -2.27% -2.8000
MPSYF closed down 2.27 percent on Monday, August 12, 2019, on 6 percent of normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Up
See historical MPSYF trend table...

Date Alert Name Type % Chg
Stochastic Sell Signal Bearish 0.00%
Slingshot Bullish Bullish Swing Setup 0.00%
Narrow Range Bar Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Overbought Stochastic Strength 0.00%
Gapped Down Weakness 0.00%
Narrow Range Bar Range Contraction -2.27%
Wide Bands Range Expansion -2.27%
Gapped Up Strength -2.27%
Overbought Stochastic Strength -2.27%

Older signals for MPSYF ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
MorphoSys developed HuCAL, the most successful antibody library technology in the pharmaceutical industry. By successfully applying this and other proprietary technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human healthcare.Together with its partners in the pharmaceutical industry, MorphoSys has built a therapeutic pipeline of drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer�s disease, to name just a few. With its ongoing commitment to new antibody technology and drug development, MorphoSys is focused on making the healthcare products of tomorrow.Over 70 therapeutic antibody programs based on the company�s technologies are currently in development, of which 20 are in clinical trials. The company�s most advanced proprietary program is MOR103, a first-in-class antibody against GM-CSF for the treatment of rheumatoid arthritis and multiple sclerosis. MOR103 is part of MorphoSys's collaboration with GlaxoSmithKline. Other proprietary clinical programs include MOR208 and MOR202, both for the treatment of cancer.MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR.
Medicine Healthcare Medical Specialties Cancer Pharmaceutical Industry Treatment Of Cancer Healthcare Products Immunology Antibodies Drug Development Monoclonal Antibodies Multiple Sclerosis Rheumatoid Arthritis Antibody Monoclonal Antibody Therapy Antibody Technology Cambridge Antibody Technology
Is MPSYF a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Indicators
Indicator Value
52 Week High 142.85
52 Week Low 36.63
Average Volume 1,800
200-Day Moving Average 82.6724
50-Day Moving Average 107.3346
20-Day Moving Average 110.0724
10-Day Moving Average 112.8648
Average True Range 4.2538
ADX 13.85
+DI 58.1036
-DI 40.0487
Chandelier Exit (Long, 3 ATRs ) 110.7386
Chandelier Exit (Short, 3 ATRs ) 103.5114
Upper Bollinger Band 127.7744
Lower Bollinger Band 92.3704
Percent B (%b) 0.8
BandWidth 32.164285
MACD Line 3.1781
MACD Signal Line 1.0326
MACD Histogram 2.1455
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 120.7000
Resistance 3 (R3) 120.7000 120.7000 120.7000
Resistance 2 (R2) 120.7000 120.7000 120.7000 120.7000
Resistance 1 (R1) 120.7000 120.7000 120.7000 120.7000 120.7000
Pivot Point 120.7000 120.7000 120.7000 120.7000 120.7000
Support 1 (S1) 120.7000 120.7000 120.7000 120.7000 120.7000
Support 2 (S2) 120.7000 120.7000 120.7000 120.7000
Support 3 (S3) 120.7000 120.7000 120.7000
Support 4 (S4) 120.7000